PALM SPRINGS, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)VIVA PHYSICIANS INC, founded in 2003, is a community nonprofit in the Education sector that reported $6.0M in total revenue in fiscal year 2023. The organization ran a surplus of $1.1M, a strong 19% operating margin.
TO SYNERGIZE THE COLLECTIVE TALENTS OF THESE RECOGNIZED EXPERTS TO PROMOTE AWARENESS AND INNOVATIVE THERAPEUTIC OPTIONS FOR VASCULAR DISEASE.
EDUCATION:THE ORGANIZATION SPONSORS VASCULAR INTERVENTIONAL ADVANCES ("VIVA"), THE GLOBAL EDUCATION COURSE FOR VASCULAR MEDICINE AND INTERVENTION. VIVA IS CONDUCTED ANNUALLY IN LAS VEGAS, NEVADA AND...
EDUCATION:THE ORGANIZATION SPONSORS VASCULAR INTERVENTIONAL ADVANCES ("VIVA"), THE GLOBAL EDUCATION COURSE FOR VASCULAR MEDICINE AND INTERVENTION. VIVA IS CONDUCTED ANNUALLY IN LAS VEGAS, NEVADA AND ON A SMALLER SCALE WITH OTHER NONPROFIT ORGANIZATIONS IN A COLLABORATIVE ROLE BOTH DOMESTICALLY AND WORLDWIDE. IN 2023, THE ANNUAL CONFERENCE WAS HOSTED LIVE AND VIRTUALLY, AND SEVERAL EDUCATIONAL WEBINARS WERE HELD THROUGHOUT THE YEAR.VIVA IS SPONSORED BY VPI AND CONTRACTS WITH AN ACCREDITED CONTINUING MEDICAL EDUCATION ("CME") PROVIDERS TO APPROVE CREDITS FOR PHYSICIAN ATTENDEES NURSES, TECHS, AND OTHER HEALTHCARE (CONTINUED ON SCH O) PROFESSIONALS. VIVA FURTHERS VPI'S EXEMPT PURPOSE AS BOTH AN ACCREDITED CONTINUING MEDICAL EDUCATION PROGRAM AND A FORUM FOR PROMOTING THE LATEST RESEARCH FINDINGS AND TECHNOLOGY IN THE FIELD OF VASCULAR MEDICINE AND INTERVENTION.IN 2015, VIVA ADDED A TWO-DAY PROGRAM, THE VEINS (VENOUS ENDOVASCULAR INTERVENTIONAL STRATEGIES), FOCUSED EXCLUSIVELY ON TREATING PATIENTS WITH VENOUS DISEASE. THIS COURSE IS HELD ANNUALLY THE TWO DAYS PRECEDING THE VIVA CONFERENCE. VPI HAS SUPPORTED A MULTIDISCIPLINARY FELLOWSHIP FOR SEVERAL YEARS. IN THE PAST SIX YEARS, ADDITIONAL OPPORTUNITIES FOR TRAINING FELLOWS HAVE BEEN INCORPORATED INTO THE ANNUAL VIVA CONFERENCE. BEGINNING IN 2018, VIVA PARTNERED WITH THE AMERICAN HEART ASSOCIATION TO PROVIDE RESEARCH GRANTS FOR FELLOWS AND PLANS TO CONTINUE THIS COLLABORATION THROUGH 2027.VIVA IS FUNDED PRIMARILY THROUGH UNRESTRICTED EDUCATIONAL GRANTS FROM COMMERCIAL SUPPORTERS IN ACCORDANCE WITH STANDARDS OF THE AMERICAN COUNCIL FOR CONTINUING MEDICAL EDUCATION ("ACCME"). VIVA ALSO GENERATES FUNDS THROUGH REGISTRATION AND TUITION PAYMENTS FROM THE CONFERENCE ATTENDEES.VPI STRIVES TO BE THE PREMIER EDUCATOR IN THE FIELD OF VASCULAR MEDICINE AND INTERVENTION AND TO ASSOCIATE THE NAME "VIVA" WITH CUTTING EDGE AND STATE-OF-THE-ART PROGRAMS THAT SERVE THE PUBLIC GOOD BY PROMOTING ADVANCES IN TREATMENT OF PERIPHERAL VASCULAR DISEASE.IN 2012, VPI EXPANDED ITS INTERNATIONAL EDUCATIONAL OPPORTUNITIES BY COLLABORATING WITH INTERNATIONAL ORGANIZATIONS TO PROVIDE STATE OF THE ART LEARNING MODALITIES AND CUTTING-EDGE PROGRAMS IN COUNTRIES SUCH AS BRAZIL, GERMANY, GREAT BRITAIN, ISRAEL AND CHINA.IN 2014, VPI LAUNCHED A VIRTUAL VIVA APPLICATION THAT MADE IT POSSIBLE FOR INTERNATIONAL AND MILITARY PHYSICIANS TO PARTICIPATE IN THE ANNUAL VIVA CONFERENCE REMOTELY. VIVA OFFERS COMPLIMENTARY ACCESS TO EDUCATIONAL CONTENT THROUGH THE VIRTUAL VIVA APP TO INTERNATIONAL PHYSICIANS AS WELL AS ALL ACTIVE MILITARY PHYSICIANS.RESEARCH:VPI SPONSORS RESEARCH AND PIONEERING THERAPY IN THE FIELD OF VASCULAR MEDICINE. VPI RECEIVES GRANTS FROM INDUSTRY AS WELL AS CONTRIBUTIONS FROM PRIVATE INDIVIDUALS IN SUPPORT OF PVD (PERIPHERAL VASCULAR DISEASE) RESEARCH.VPI HAS MANAGED SEVERAL FOOD AND DRUG ADMINISTRATION ("FDA") APPROVED STUDIES RELATED TO PVD TREATMENT. THESE TRIALS FOLLOW GOOD CLINICAL PRACTICE ("GCP") PROTOCOLS AND REQUIRE STRICT INSTITUTIONAL REVIEW BOARD ("IRB") APPROVAL AT EACH SITE.ADVOCACY:AS PART OF VPI'S STRATEGIC PLAN, PATIENT CARE ADVOCACY PROGRAMS, FOCUSED ON ADVANCING THE FIELD OF VASCULAR DISEASE CARE, ARE PLANNED TO INCLUDE THOUGHT LEADERS AND GOVERNMENT AGENCIES, INCLUDING THE FDA AND CENTERS FOR MEDICARE & MEDICAID SERVICES ("CMS"). THE FIRST PROGRAM WAS HELD APRIL 2016 AND FOCUSED ON THE GLOBAL MANAGEMENT OF CRITICAL LIMB ISCHEMIA, ONE OF THE MOST CHALLENGING PATIENT DISORDERS. THE SECOND "VASCULAR DISEASE FORUM" OCCURRED IN MAY 2018, FOCUSING ON TREATMENT AND MANAGEMENT OF CAROTID ARTERY DISEASE AND THE MOST RECENT FORUM IN FEBRUARY 2019 FOCUSED ON THE RECENT META-ANALYSIS ON THE SAFETY OF PACLITAXEL. VPI HAS TAKEN THE LEAD IN ANALYZING PATIENT LEVEL DATA TO HELP ANSWER THE QUESTION OF PATIENT SAFETY. THESE FINDINGSWERE RECENTLY PUBLISHED IN A PEER-REVIEWED JOURNAL, CIRCULATION. IN 2022, VPI SPONSORED ANOTHER FORUM WITH THE TOPIC ADDRESSING PRESSING ISSUES RELATED TO VENOUS STENTING AND THROMBECTOMY, WHICH RESULTED IN A PUBLISHED PAPER. IN 2023, VPI SPONSORED A FOLLOW-UP NIVL ROUNDTABLE RESULTING IN A PUBLISHED PAPER. VPI WILL BE HOSTING ANOTHER VASCULAR DISEASE FORUM IN 2024.DURING THE YEAR, TOTAL OF APPROXIMATELY 1120 PEOPLE WERE SERVED FOR VIVA CONFERENCE AND FOR VEINS (TWO DAY PROGRAM).
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $5,950,071 | $5,717,586 | +0.0% |
| Expenses | $4,827,351 | $5,367,452 | -0.1% |
| Net Income | $1,122,720 | $350,134 | +2.2% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| MAUREEN KOHI MD | BOARD PROGRAM CHAIR | 3.00 |
Officer
Director
|
$22,750 | $0 | $22,750 |
| NITEN SINGH MD | BOARD PROGRAM CHAIR | 3.00 |
Officer
Director
|
$45,000 | $0 | $45,000 |
| RAGHU KOLLURI MD | BOARD PRESIDENT | 3.00 |
Officer
Director
|
$70,000 | $0 | $70,000 |
| VENITA CHANDRA MD | BOARD SECRETARY/TREASURER | 3.00 |
Officer
Director
|
$22,813 | $0 | $22,813 |
| EHRIN ARMSTRONG MD | BOARD TRUSTEE | 3.00 |
Director
|
$23,500 | $0 | $23,500 |
| JOSHUA A BECKMAN MD | BOARD TRUSTEE | 3.00 |
Director
|
$25,000 | $0 | $25,000 |
| SEAN P LYDEN MD | BOARD TRUSTEE | 3.00 |
Director
|
$25,000 | $0 | $25,000 |
| CHRISTOPHER METZGER MD | BOARD TRUSTEE | 3.00 |
Director
|
$25,000 | $0 | $25,000 |
| SAHER SABRI MD | BOARD TRUSTEE | 3.00 |
Director
|
$28,500 | $0 | $28,500 |
| PETER SCHNEIDER MD | BOARD TRUSTEE (THRU 12/23) | 3.00 |
Director
|
$22,250 | $0 | $22,250 |
| PARAG PATEL MD | BOARD TRUSTEE | 3.00 |
Director
|
$21,500 | $0 | $21,500 |
| ERIC SECEMSKY MD | BOARD TRUSTEE | 3.00 |
Director
|
$25,000 | $0 | $25,000 |
| REBECCA HALL | EXECUTIVE DIRECTOR | 40.00 |
Officer
|
$396,595 | $28,856 | $425,451 |
| CHRISTOPHER EBBE | DIRECTOR OF PROGRAMS | 40.00 |
Highest
|
$251,327 | $35,021 | $286,348 |
| THERESA KINANE | DIRECTOR OF FINANCE & LOGISTICS | 40.00 |
Highest
|
$149,231 | $7,148 | $156,379 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $5,950,071 | $4,827,351 | $24,393,940 | $1,122,720 |
| 2022 | $5,717,586 | $5,367,452 | $22,100,991 | $350,134 |
| 2021 | $7,273,645 | $4,295,095 | $23,221,286 | $2,978,550 |
| 2021 | $5,506,798 | $4,295,095 | $23,221,286 | $1,211,703 |
| 2020 | $3,377,462 | $3,760,186 | $21,094,201 | $-382,724 |
| 2019 | $7,051,789 | $5,959,268 | $20,851,746 | $1,092,521 |
| 2018 | $7,381,426 | $5,734,900 | $19,168,254 | $1,646,526 |
Compare VIVA PHYSICIANS INC with other nonprofits in California and across the country.